Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
NCT03824392Phase 2Completed
- Sponsor
- aTyr Pharma
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efzofitimod in pulmonary sarcoidosis (4 arms), sponsored by aTyr Pharma. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
efzofitimod
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT03824392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824392.